These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Approaches to rational drug development in Alzheimer's disease. Iversen LL; Iversen SD; Freedman SB; Dawson G; Rupniak N; Hargreaves RJ; Showell GA; Street LJ; Baker R Drug Des Discov; 1993; 9(3-4):251-9. PubMed ID: 8400006 [No Abstract] [Full Text] [Related]
9. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. Hampel H; Ewers M; Bürger K; Annas P; Mörtberg A; Bogstedt A; Frölich L; Schröder J; Schönknecht P; Riepe MW; Kraft I; Gasser T; Leyhe T; Möller HJ; Kurz A; Basun H J Clin Psychiatry; 2009 Jun; 70(6):922-31. PubMed ID: 19573486 [TBL] [Abstract][Full Text] [Related]
10. Dementia and Alzheimer's disease. Indications, diagnosis, and treatment. Golden R Minn Med; 1995 Jan; 78(1):25-9. PubMed ID: 7877576 [TBL] [Abstract][Full Text] [Related]
11. NGF and the treatment of Alzheimer's disease. Olson L Exp Neurol; 1993 Nov; 124(1):5-15. PubMed ID: 8282080 [TBL] [Abstract][Full Text] [Related]
12. [Use of neuropsychological tests in the Cronos Project]. Bianchi G; Gasparini M; Caffari B; Sorrentino GC; Bianchi C; Bruno G; Maggini M; Raschetti R; Vanacore N Ann Ist Super Sanita; 2005; 41(1):69-74. PubMed ID: 16037653 [TBL] [Abstract][Full Text] [Related]
13. Measuring cognitive change in Alzheimer's disease clinical drug trials. Harrison JE J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492 [TBL] [Abstract][Full Text] [Related]
14. Assessment of treatment-associated changes in behavior and cholinergic therapy of neuropsychiatric symptoms in Alzheimer's disease. Cummings JL; Masterman DL J Clin Psychiatry; 1998; 59 Suppl 13():23-30. PubMed ID: 9771827 [TBL] [Abstract][Full Text] [Related]
15. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Browne P; Wasser D; Johnson-Traver S; Lochhead J; Ziolwolski C Arch Neurol; 2005 May; 62(5):753-7. PubMed ID: 15883262 [TBL] [Abstract][Full Text] [Related]
16. Mild cognitive impairment, healthy aging and Alzheimer's disease. Wu CK Med Health R I; 2008 May; 91(5):132-3. PubMed ID: 18549037 [No Abstract] [Full Text] [Related]
17. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine]. Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553 [TBL] [Abstract][Full Text] [Related]
18. FPIN's clinical inquiries. Monitoring therapy for patients with Alzheimer's disease. Raetz J; v d Luft E Am Fam Physician; 2007 Jun; 75(11):1703-4. PubMed ID: 17575663 [No Abstract] [Full Text] [Related]
19. Long term safety and efficacy of donepezil in the treatment of dementia in Alzheimer's disease in adults with Down syndrome: open label study. Prasher VP; Adams C; Holder R; Int J Geriatr Psychiatry; 2003 Jun; 18(6):549-51. PubMed ID: 12789681 [No Abstract] [Full Text] [Related]
20. Galantamine improves gait performance in patients with Alzheimer's disease. Assal F; Allali G; Kressig RW; Herrmann FR; Beauchet O J Am Geriatr Soc; 2008 May; 56(5):946-7. PubMed ID: 18454755 [No Abstract] [Full Text] [Related] [Next] [New Search]